NASDAQ:COCP

Cocrystal Pharma Q3 2026 Earnings Results & Report

Cocrystal Pharma logo
$0.98 -0.03 (-3.28%)
Closing price 04:00 PM Eastern
Extended Trading
$0.98 +0.01 (+0.83%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cocrystal Pharma missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.20 versus the -$0.18 consensus estimate, while revenue of $110 thousand topped the $105 thousand estimate by $5.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens

Cocrystal Pharma EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Cocrystal Pharma Revenue Results

Actual Revenue
$110 thousand
Expected Revenue
$105 thousand
Beat/Miss
Beat by +$5.00 thousand
YoY Revenue Growth
N/A

Cocrystal Pharma Q3 2026 Earnings FAQ

Cocrystal Pharma (NASDAQ:COCP) reported earnings of -$0.20 per share for Q3 2026, missing the consensus estimate of -$0.18. The report was announced on Monday, November 16, 2026.

Cocrystal Pharma reported revenue of $110 thousand for Q3 2026, against a consensus estimate of $105 thousand.

Cocrystal Pharma Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses.

The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.

Cocrystal Pharma is based in Bothell, Washington. It has concentrated on antiviral drug development rather than marketing commercial medicines, and its programs and research priorities may change as development progresses.

View Cocrystal Pharma Profile